Anti-IgE monoclonal antibody, omalizumab: a new treatment for allergic asthma

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.5, Iss.2, 2004-02, pp. : 439-446

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-IgE Monoclonal Antibody (Omalizumab) in the Treatment of Atopic Asthma and Allergic Respiratory Diseases

Current Drug Targets. Inflammation & Allergy, Vol. 3, Iss. 3, 2004-09 ,pp. : 227-229

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-IgE monoclonal antibody E25 beneficial in allergic asthma

Inpharma, Vol. 1, Iss. 1220, 2000-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Novel anti-IgE monoclonal antibody promising against allergic diseases

Inpharma, Vol. 1, Iss. 1232, 2000-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Anti-IgE Therapy in Allergic Asthma

Current Drug Targets. Inflammation & Allergy, Vol. 4, Iss. 5, 2005-10 ,pp. : 551-564

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-IgE Therapy with Omalizumab for Severe Asthma: Current Concepts and Potential Developments

Current Drug Targets, Vol. 16, Iss. 2, 2015-02 ,pp. : 171-178

Bentham Science Publishers

Access to resources Recommend Favorite